Divesting assets, increasing innovation—can Hutchison Medicine break through?

21st Century Business Herald Reporter Yan Shuo

On the evening of March 5th, Hutchison MediPharma released its full-year 2025 performance report. The total revenue for the year was $549 million, a 12.96% decrease year-over-year; net profit reached $457 million, a significant increase of 1111.03% year-over-year, marking three consecutive years of profitability.

In terms of market sales, Hutchison MediPharma achieved $525 million in annual revenue, with overseas revenue outside China reaching $366 million, a 26% increase from last year. However, due to multiple factors, domestic revenue declined 25% year-over-year to $159 million, dragging down overall performance. The sharp increase in net profit was mainly due to non-recurring gains from the sale of equity in Shanghai Hutchison Pharmaceuticals.

Industry analysts believe that the revenue pressure faced by Hutchison MediPharma reflects the challenges of domestic oncology drugs under centralized procurement and competitive pressure. Meanwhile, its profit surge reveals the company’s strategic focus on asset optimization to unlock value and concentrate on core pipelines.

Founded in 2000, Hutchison MediPharma is an innovative international biopharmaceutical company under Li Ka-shing, integrating R&D, manufacturing, and commercialization. Currently, the company has 13 clinical-stage drug candidates, including four approved for listing in China: Fuzulitinib, Sorafenib, Savolitinib, and Tazemetostat. Fuzulitinib has been approved or listed in 39 countries worldwide, including China, the US, the EU, and Japan.

Meanwhile, the fifth drug, Soleritinib, has been submitted for a new drug listing in China, with a second application in preparation. In early-stage drug discovery and development, the company is steadily advancing its ATTC (antibody-targeted conjugate) platform, with two products entering global Phase I clinical trials.

In the context of policy changes and intensified market competition, how is Hutchison MediPharma planning to break through?

Revenue Decline

Looking at Hutchison MediPharma’s recent financial reports, the company’s performance has been under pressure for two consecutive years. In 2024, revenue was $630 million, down 24.80% year-over-year; in 2025, total revenue was $549 million, down 12.96%. This decline is not due to a single product failure but results from multiple structural adjustments.

Its oncology/immunology business had a combined revenue of $286 million, down 21.44%, mainly due to weak sales of three core products in China. Aiyoute (Fuzulitinib) in China generated $100 million, down 13%; Suteda (Sorafenib) earned $27 million, down 45%; Voresta (Savolitinib) brought in $28.9 million, down 36%.

Product/Business Revenue Breakdown｜Source: Hutchison MediPharma 2025 Annual Report

Among these, the core product Aiyoute, used for third-line and above treatments of metastatic colorectal cancer (mCRC), faces competition from regorafenib and trifluorouracil derivatives. Regorafenib tablets have been included in the tenth batch of national centralized procurement, effective from April 2025, directly impacting its market.

In stark contrast, overseas markets showed significant growth. Sales of FRUZAQLA (the international brand name for Fuzulitinib), managed by Takeda Japan, reached $366 million, a 26% increase, becoming a key revenue pillar. This growth is driven by demand for innovative chemo-free treatment options in colorectal cancer and positive experiences from oncologists using the drug in third-line or higher settings. Nearly 20 countries have included this product in their medical insurance coverage.

Additionally, milestone payments from licensing collaborations have become important revenue supplements. Voresta’s approval for a third indication in lung cancer in China triggered a $11 million milestone payment from AstraZeneca.

Notably, the $20 million milestone payment from Takeda in 2024 was not repeated in 2025, further lowering overall revenue growth. Industry experts believe this revenue volatility is typical for innovative drug companies operating under a BD (business development) model, where income is increasingly tied to R&D milestones and licensing events rather than stable product sales.

To counter regulatory and commercialization challenges, Hutchison MediPharma streamlined and repositioned its sales team in 2025, reducing total sales and administrative expenses to $103 million, an 8.8% decrease. In the second half of 2025, sales increased by 24% compared to the first half, with Aiyoute sales rising 33% in the second half, indicating initial success of reforms. The company’s guidance for 2026 oncology/immunology revenue is between $330 million and $450 million, representing over 50% year-over-year growth at the high end.

On March 6th, Hutchison MediPharma’s stock opened sharply higher and then fluctuated, briefly rising over 10% during the day. By close, the stock was at HKD 22.18, up 5.32%, with a market capitalization of approximately HKD 19.348 billion.

Increasing Focus on Innovation

Despite revenue declines, Hutchison MediPharma’s net profit in 2025 soared to $457 million, a 1111.03% increase, mainly driven by non-recurring gains rather than core business performance.

In April 2025, the company sold a 45% stake in Shanghai Hutchison Pharmaceuticals for $608.5 million in cash, retaining a 5% stake. The transaction resulted in an after-tax net gain of about $416 million, accounting for most of the profit increase. Excluding this one-time gain, the core business’s net profit remains modest, with significant profit potential yet to be unlocked.

The improved profit structure also benefits from ongoing cost optimization. R&D expenses in 2025 fell to $148.3 million, down 30.08% year-over-year. This reduction is not due to a lack of innovation but a strategic focus of resources.

Hutchison MediPharma states that since the high-cost late-stage clinical trials of candidate drugs have been completed and supported new drug applications and approvals, R&D spending has decreased. Meanwhile, the company plans to accelerate global clinical trials for early-stage ATTC (antibody-targeted conjugate) projects.

The ATTC platform, as the company’s future growth engine, has entered a critical phase. This platform uses targeted small molecules as payloads, differing from traditional ADCs (antibody-drug conjugates), with lower off-target toxicity and stronger potential for combination therapies. Currently, ATTC candidates are in clinical trials.

Following preclinical data presentation at the AACR-NCI-EORTC conference in October 2025, the company launched the first clinical trial of its ATTC candidate HMPL-A251 in December 2025; clinical trials for HMPL-A580 began in March 2026; and the third candidate, HMPL-A830, is planned to start Phase I trials before the end of 2026.

Hutchison MediPharma is also negotiating licensing agreements with multiple multinational pharmaceutical companies for the ATTC platform, which could become a significant future revenue source.

Additionally, as of the end of 2025, the company’s cash reserves reached $1.3673 billion, providing solid support for ongoing R&D and collaborations.

CICC International analysts note that with the completion of sales team adjustments and the diminishing marginal impact of US Medicare policy changes, they expect rapid growth in domestic and international sales of four commercialized products in 2026. Furthermore, Soleritinib’s ITP (resubmission) and wAIHA (autoimmune hemolytic anemia) indications are expected to submit NDA applications in 2026, with approval anticipated in 2027. After short-term clinical and commercialization fluctuations, the company’s overall operations are expected to gradually return to normal from 2026, with multiple catalysts potentially restoring valuation.

In other words, as clinical data for ATTC platform disclosures and approvals for Soleritinib and other new drugs like Fandrigra become available, Hutchison MediPharma may enter a new growth cycle. However, the market should remain rational, paying attention to whether core products can achieve sustainable volume growth under insurance coverage and whether overseas collaborations can be successfully implemented as scheduled.